Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC19410.15690/vramn.v68i4.609RHEUMATOLOGY: CURRENT ISSUESАКТУАЛЬНЫЕ ВОПРОСЫ РЕВМАТОЛОГИИIMMUNOGENETIC ASPECTS ОF EARLY RHEUMATOID ARTHRITISИММУНОГЕНЕТИЧЕСКИЕ АСПЕКТЫ РАННЕГО РЕВМАТОИДНОГО АРТРИТАGusevaI. A.ГусеваИ. А.
Russian Federation

PhD, Senior Research Worker, Laboratory of Clinical Immunology and Molecular Biology of Rheumatic Diseases, Research Institute of Rheumatology Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499) 615-93-07

irrgus@yandex.ruDemidovaN. V.ДемидоваН. В.
Russian Federation

PhD, Research Worker, Department of Early Arthritis, Research Institute of Rheumatology Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499) 614-42-79

natasha-demidova@mail.ruSorokaN. E.СорокаН. Е.
Russian Federation

Research Worker of Scientific and Production Department, Research and Production Company DNA Technology. Address: 115478, Moscow, Kashirskoye Highway 2/2; tel.: (495) 980-45-55

nataliyasoroka@yandex.ruNovikovA. A.НовиковА. А.
Russian Federation

PhD, Leading Research Worker, Laboratory of Clinical Immunology and Molecular Biology of Rheumatic Diseases, Research Institute of Rheumatology Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499) 614-09-33

irramnlab@rambler.ruLuchikhinaE. L.ЛучихинаЕ. Л.
Russian Federation

PhD, Leading Research Worker, Department of Early Arthritis, Research Institute of Rheumatology Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499) 614-42-79

eleluch@yandex.ruAleksandrovaE. N.АлександроваЕ. Н.
Russian Federation

PhD, Head of the Laboratory of Clinical Immunology and Molecular Biology of Rheumatic Diseases, Research Institute of Rheumatology Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499) 614-09-33

irramnlab@rambler.ruLukinaG. V.ЛукинаГ. В.
Russian Federation

PhD, Head of the Laboratory of Clinical Pharmacology, Research Institute of Rheumatology Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499) 618-92-38

gvl3@yandex.ruFedorenkoE. V.ФедоренкоЕ. В.
Russian Federation

PhD, Junior Research Worker, Laboratory of Clinical Pharmacology Research Institute of Rheumatology Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499) 618-92-38

ev_f@bk.ruAronovaE. S.АроноваЕ. С.
Russian Federation

PhD, Junior Research Worker, Laboratory of Clinical Pharmacology Research Institute of Rheumatology Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499) 618-92-38

eugpozd@mail.ruSamarkinaE. Yu.СамаркинаЕ. Ю.
Russian Federation

Junior Research Worker, Laboratory of Clinical Immunology and Molecular Biology of Rheumatic Diseases, Research Institute of Rheumatology Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499) 615-93-07

samarkinale@list.ruBoldyrevaM. N.БолдыреваМ. Н.
Russian Federation

PHD, Leading Research Worker, Department of Immunogenetics, Institute of Immunology. Address: 115478, Kashirskoye Highway 24/2; tel.: (499) 617-78-22

rita@dna-technology.ruTrofimovD. Yu.ТрофимовД. Ю.
Russian Federation

PhD, General Director of Research and Production Company DNA Technology. Address: 115478, Kashirskoye Highway 24/2; tel.: (495) 980-45-55

molgen@bk.ruKarateevD. E.КаратеевД. Е.
Russian Federation

PhD, Head of Department of Early Arthritis, Research Institute of Rheumatology Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499)614-31-73

dekar@inbox.ruNasonovE. L.НасоновЕ. Л.
Russian Federation

PhD, Professor, RAMS academician, Director of Research Institute of Rheumatology, Russian Academy of Medical Sciences Address: 115522, Moscow, Kashirskoye Highway, 34A; tel.: (499) 614-44-90

sokrat@irramn.ruResearch Institute of Rheumatology RAMS, Moscow, Russian FederationНаучно-исследовательский институт ревматологии РАМН, Москва, Российская ФедерацияJoint Stock Company «DNA-Technology», Moscow, Russian FederationНаучно-производственная фирма «ДНК-Технология», Москва, Российская ФедерацияNational Research Centre Institute of Immunology FMBA, Moscow, Russian FederationИнститут иммунологии ФМБА, Москва, Российская Федерация14042013684Vestnik Rossiiskoi akademii medetsinskikh nauk / Annals of the Russian academy of medical sciencesВестник Российской академии медицинских наук364307082015Copyright ©; 1970, "Paediatrician" Publishers LLCCopyright ©; 1970, Издательство "Педиатръ"1970"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/article/view/194

The study is aimed to investigate the distribution of alleles of HLA-DRB1 gene in patients with early rheumatoid arthritis and healthy individuals in Russian population, and evaluate their significance as molecular genetic markers of rheumatoid arthritis predisposition and protection. The association between alleles of HLA-DRB1 genes, antibodies to cyclic citrullinated peptides and IgM rheumatoid factor was also studied. Low and high resolution HLA-DRB1 genotyping were compared. In the cohort of patients with early rheumatoid arthritis, the alleles of HLA-DRB1 gene were found to be markers of rheumatoid arthritis protection/risk, especially in the homozygous state. They determined production of antibodies to cyclic citrullinated peptides but were not associated with rheumatoid factor IgM levels. These findings support different autoimmune mechanisms of rheumatoid arthritis pathogenesis.

Изучено распределение аллелей гена HLA-DRB1 у больных ранним ревматоидным артритом и здоровых лиц контрольной группы российской популяции и оценена их значимость в качестве молекулярно-генетических маркеров предрасположенности и протекции ревматоидного артрита. Определена сила ассоциативной связи аллелей гена HLA-DRB1 с продукцией антител к циклическим цитруллинированным пептидам и ревматоидному фактору класса М. В исследовании проведено сравнение методов высоко- и низкоразрешающего генотипирования аллелей HLA-DRB1. У больных ранним ревматоидным артритом обнаружены аллели гена HLA-DRB1, являющиеся маркерами риска и протекции ревматоидного артрита, детерминирующие продукцию антител к циклическим цитруллинированным пептидам, но не ассоциированные с антителами класса M к ревматоидному фактору. Полученные данные могут свидетельствовать о различных аутоиммунных механизмах патогенеза ревматоидного артрита.

rheumatoid arthritisHLA-DRB1shared epitopeantibodies to cyclic citrullinated peptidesrheumatoid factorревматоидный артритHLA-DRB1shared epitopeантитела к циклическим цитруллинированным пептидамревматоидный фактор1. Nasonov E.L., Karateev D.E., Balabanova R.M. Revmatoidnyi artrit. V kn.: Revmatologiya. Natsional'noe rukovodstvo. Pod redaktsiei E.L. Nasonova, V.A. Nasonovoi [Rheumatoid Arthritis. In: Rheumatology. National Guideline. Edited by E.L. Nasonov, V.A. Nasonova]. Moscow, GEOTAR-Media, 2008. p. 290–331.2. de Rooy D.P.C., van der Linden M.P.M., Knevel R., de Rooy D.P., van der Linden M.P., Knevel R., Huizinga T.W., van der Helm-van Mil A.H. Predicting arthritis outcomes — what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2010; 51 (1): 93–100.3. Novikov A.A., Aleksandrova E.N., Nasonov E.L. The clinical significance of antibodies to cyclic citrullinated peptide: the new data. Klin. meditsina = Clinical medicine. 2007; 85 (8): 4–9.4. Niewold T.B., Harrison M.J., Paget S.A. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM. 2007; 100 (4): 193–201.5. van Venrooij W.J., Zendman A.J. Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis. Clin. Rev. Allergy. Immunol. 2008; 34 (1): 36–39.6. Aggarwal R., Liao K., Nair R. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum. 2009; 61 (11): 1472–1483.7. Aletaha D., Neogi .T, Silman A.J., Funovits J., Felson D.T., Bingham C.O., 3rd, Birnbaum N.S., Burmester G.R., Bykerk V.P., Cohen M.D., Combe B., Costenbader K.H., Dougados M., Emery P., Ferraccioli G., Hazes J.M., Hobbs K., Huizinga T.W., Kavanaugh A., Kay J., Kvien T.K., Laing T., Mease P., Ménard H.A., Moreland L.W., Naden R.L., Pincus T., Smolen J.S., Stanislawska-Biernat E., Symmons D., Tak P.P., Upchurch K.S., Vencovský J., Wolfe F., Hawker G. The 2010 American College of Rheumatology / European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis. Arthritis Rheum. 2010; 62 (9): 2569–2581.8. Rantapää-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., Sundin U., van Venrooij W.J. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48 (10): 2741–2749.9. Kokkonen H., Mullazehi M., Berglin E., Hallmans G., Wadell G., Rönnelid J., Rantapää-Dahlqvist S. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthr. Res. Ther. 2011; 13 (1): 13.10. McAllister K.M., Eyre S., Orozco G. Genetics of rheumatoid arthritis: GWAS and beyond. Review. Open Access Rheumatology: Research and Reviews. 2011; 3: 31–46.11. Gregersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987; 30 (11): 1205–1213.12. van der Horst-Bruinsma I.E., Visser H., Hazes J.M., Breedveld F.C., Verduyn W., Schreuder G.M., de Vries R.R., Zanelli E. HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis. Hum. Immunol. 1999; 60 (2): 152–158.13. Mattey D.L., Dawes P.T., Gonzalez-Gay M.A., Garcia-Porrua C., Thomson W., Hajeer A.H., Ollier W.E. HLA-DRB1 alleles encoding an aspartic acid at position 70 protect against development of rheumatoid arthritis. Rheumatology. 2001; 28 (2): 232–239.14. de Vries N., Tijssen H., van Riel P.L., van de Putte L.B. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67–74 of the HLA-DRB1 molecule. Arthritis Rheum. 2002; 46 (4): 921–928.15. du Montcel S.T., Michou L., Petit-Teixeira E., Osorio J., Lemaire I., Lasbleiz S., Pierlot C., Quillet P., Bardin T., Prum B., Cornelis F., Clerget-Darpoux F. New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis Rheum. 2005; 52 (4): 1063–1068.16. Guseva I.A., Nasonov E.L. Modern immunogenetic and immunologic aspects of rheumatoid arthritis. Vestnik RAMN = Annals of RAMS. 2008; 6: 7–13.17. Boldyreva M.N., Grudakova E.G., Bukina A.M. et al. Raspredelenie HLA-DRB1*04 v semi etnicheskikh gruppakh Rossii. Mat-ly II (IV) ross. s"ezda meditsinskikh genetikov [The Distribution of HLA-DRB1 * 04 in Seven Ethnic Groups in Russia. Materials of II (IV) Russian Congress of Medical Geneticists]. Kursk, 17–19 maya 2000. p. 156–157.18. Nishimura K., Sugiyama D., Kogata Y., Tsuji G., Nakazawa T., Kawano S., Saigo K., Morinobu A., Koshiba M., Kuntz K.M., Kamae I., Kumagai S. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann. Intern. Med. 2007; 146 (11): 797–808.19. Guseva I.A., Myakotkin V.A., Sharapova E.P., Samarkina E.Yu. Allelic polymorphism of HLA-DRB1 * 04 and a family rheumatoid arthritis. Nauch.-prakt. revmatol. = Scientific and practical rheumatology. 2001; 3: 32.20. Myakotkin V.A., Moshnina M.A., Krylov M.Yu., Guseva I.A. Search susceptibility genes of rheumatoid arthritis. Vestnik RAMN = Annals of RAMS. 2003; 7: 27–30.21. Taukumova L.A., Guseva I.A. HLA-DRB1 alleles in patients with rheumatoid arthritis. Nauch.-prakt. revmatol. = Scientific and practical rheumatology. 2004; 4: 29–3422. van der Helm-van Mil A.H., Huizinga T.W. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res. Ther. 2008; 10 (2): 205.23. Padyukov L., Seielstad M., Ong R.T., Ding B., Rönnelid J., Seddighzadeh M., Alfredsson L., Klareskog L.A. genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann. Rheum. Dis. 2011; 70 (2): 259–265.24. Meyer O., Labarre C., Dougados M., Goupille P., Cantagrel A., Dubois A., Nicaise-Roland P., Sibilia J., Combe B. Anticitrullinated protein / peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann. Rheum. Dis. 2003; 62 (2): 120–126.25. van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., de Jong B.A., Breedveld F.C., Verweij C.L., Toes R.E., Huizinga T.W Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthr. Rheum. 2004; 50 (3): 709–715.26. Kastbom A., Strandberg G., Lindroos A., Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann. Rheum. Dis. 2004; 63 (9): 1085–1089.27. Quinn M.A., Gough A.K., Green M.J., Devlin J., Hensor E.M., Greenstein A., Fraser A., Emery P. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (UK). 2006; 45 (4): 478-480.28. van der Helm-van Mil A.H., Verpoort K.N., Breedveld F.C., Huizinga T.W., Toes R.E., de Vries R.R. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2007; 54 (4): 1117–1121.29. Ding B., Padyukov L., Lundström E., Seielstad M., Plenge R.M., Oksenberg J.R., Gregersen P.K., Alfredsson L., Klareskog L. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum. 2009; 60 (1): 30–38.30. Hill J.A., Southwood S., Sette A., Jevnikar A.M., Bell D.A., Cairns E. Cutting Edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC Class II molecule. J. Immunol. 2003; 171 (2): 538–541.31. van der Woude D., Lie B.A., Lundström E., Balsa A., Feitsma A.L., Houwing-Duistermaat J.J., Verduijn W., Nordang G.B., Alfredsson L., Klareskog L., Pascual-Salcedo D., Gonzalez-Gay M.A., Lopez-Nevot M.A., Valero F., Roep B.O., Huizinga T.W., Kvien T.K., Martín J., Padyukov L., de Vries R.R., Toes R.E. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum. 2010; 62 (2): 1236–1245.32. Viatte S., Plant D., Bowes J., Lunt M., Eyre S., Barton A., Worthington J. Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann. Rheum. Dis .2012; 71 (12): 1984–1990.33. Huizinga T.W., Amos C.I., van der Helm-van Mil A.H., Chen W., van Gaalen F.A., Jawaheer D., Schreuder G.M., Wener M., Breedveld F.C., Ahmad N., Lum R.F., de Vries R.R., Gregersen P.K., Toes R.E., Criswell L.A. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005; 52 (11): 3433–3438.